HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

FDA Approves Adjuvant T-DM1 in HER2+ Early Breast Cancer

May 4th 2019

The FDA has approved ado-trastuzumab emtansine (T-DM1; Kadcyla) for use as an adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant trastuzumab and chemotherapy.

Dr. Mortimer on Adjuvant Therapy in Early-Stage HER2+ Breast Cancer

May 3rd 2019

Joanne Mortimer, MD, associate director for Education and Training, Comprehensive Cancer Center, Baum Family Professor in Women’s Cancers, vice chair and professor, Department of Medical Oncology & Therapeutics Research, director, Women’s Cancer Programs, City of Hope, discusses adjuvant therapy in early-stage HER2-positive breast cancer.

New VENTANA HER2 ISH DNA Assay Launches for Breast, Gastric Cancers

April 23rd 2019

A new VENTANA HER2 dual in situ hybridization companion diagnostic assay has launched to identify HER2 amplification for patients with breast cancer and gastric cancer who could be eligible to receive trastuzumab.

Landmark Approvals Lead to Continual Progress in HER2+ Breast Cancer

April 18th 2019

Cindy Osborne, MD, highlights the many advances that have been made in the treatment paradigms of locally advanced and metastatic HER2-positive breast cancer.

Dr. Hamilton on Overcoming Resistance to HER2-Targeted Therapy in Breast Cancer

April 11th 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses overcoming resistance to HER2-targeted therapy in breast cancer.

HER2+ Breast Cancer Paradigm Evolving With Practice-Changing New Options

April 9th 2019

Mark D. Pegram, MD, highlights data from pivotal studies that have helped to shape the current landscape of HER2-positive breast cancer and sheds light on emerging agents that are showing promise in the pipeline.

Dr. Cobleigh on Antibody-Drug Conjugates in Development in HER2+ Breast Cancer

April 4th 2019

Melody A. Cobleigh, MD, professor of medical oncology at Rush University Medical Center, discusses antibody–drug conjugates (ADCs) under development in HER2-positive breast cancer.

[Fam]-Trastuzumab Deruxtecan Accelerates Through HER2+ Breast Cancer Pipeline

March 29th 2019

An accelerated filing of a biologics license application is planned for [fam-] trastuzumab deruxtecan (DS-8201) as a treatment for patients with HER2-positive metastatic breast cancer previously treated with ado-trastuzumab emtansine.

Dr. Hurvitz on Toxicity Associated With Neratinib in HER2+ Breast Cancer

March 26th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses toxicity associated with neratinib in the treatment of patients with HER2-positive breast cancer.

HER2+ Breast Cancer Paradigm Slated to Expand With Novel Therapies

March 26th 2019

Melody A. Cobleigh, MD, sheds light on novel treatment approaches for patients with HER2-positive breast cancer that are under investigation as well as strategies that have already been incorporated into practice.

Dr. Pegram on Promising Novel Agents in HER2+ Metastatic Breast Cancer

March 22nd 2019

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses promising novel agents in the treatment of patients with HER2-positive metastatic breast cancer.

Hurvitz Highlights Emerging Agents for Heavily Pretreated HER2+ Breast Cancer

March 21st 2019

Sara A. Hurvitz, MD, discusses recent updates in the paradigm and promising therapeutic strategies on the horizon for patients with HER2-positive metastatic breast cancer.

Dr. Malamud on Key Data From KATHERINE Study in HER2+ Breast Cancer

March 20th 2019

Stephen C. Malamud, MD, associate professor, Icahn School of Medicine, Mount Sinai Health System, discusses key data from the KATHERINE study in the treatment of patients with HER2-positive breast cancer.

Dr. Hurvitz on Standards of Care in HER2+ Breast Cancer

March 14th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the first- and second-line standards of care in HER2-positive breast cancer.

Dr. Chien on Tucatinib in HER2+ Breast Cancer

March 12th 2019

A. Jo Chien, MD, associate clinical professor, Department of Medicine, University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the use of tucatinib (ONT-380) in the treatment of patients with HER2-positive breast cancer.

Novel Agents May Change Paradigm for Advanced HER2+ Breast Cancer

March 11th 2019

The treatment of patients with advanced HER2-positive breast cancer could be reshaped in the next several years as clinical trials of several exciting new drugs begin to yield results.

Dr. Hurvitz on FDA Approval of Subcutaneous Trastuzumab Formulation in HER2+ Breast Cancer

March 9th 2019

Sara A. Hurvitz, MD, director of the Breast Oncology Program, medical director of the Clinical Research Unit, University of California, Los Angeles Jonsson Comprehensive Cancer Center, discusses the recent FDA approval of subcutaneous use of trastuzumab (Herceptin) and hyaluronidase-oysk injection (Herceptin Hylecta) in the HER2-positive breast cancer space.

Dr. Hamilton on FDA Approval of Atezolizumab/Nab-Paclitaxel in TNBC

March 8th 2019

Erika P. Hamilton, MD, director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute, discusses the FDA approval of atezolizumab and nab-paclitaxel as a frontline therapy for patients with unresectable locally advanced or metastatic PD-L1–positive triple-negative breast cancer.

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, director, Breast and Gynecologic Research Program, Sarah Cannon Research Institute, discusses the optimal duration of trastuzumab (Herceptin) in patients with HER2-positive breast cancer.

Novel Agents, Approaches Drive Progress in HER2+ Breast Cancer

March 2nd 2019

Erika P. Hamilton, MD, shares insight on the management of patients with HER2-positive breast cancer and strategies aimed at targeting treatment resistance and toxicity.